spero therapeutics cmo

LONDON and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- GSK (LSE/NYSE: GSK) and Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced they have entered into an exclusive license. Prior to her time at Sanofi, Ms. Tregoning spent more than 10 years at Biogen, first as Vice President, Public Policy & Government Affairs and then as Senior Vice President, Corporate Affairs. Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial . Disturbing Truth About Biden's New Program To Seize Your Cash, A 73-Year-Old Market Signal With 95% Accuracy Just Flashed. Spero has engaged with the FDA on the tebipenem HBr clinical program and expects to provide an update in the first half of 2023 on the status of the SPA and detail of the Phase 3 clinical protocol. SPR206 may be able to provide a new treatment paradigm for multi-drug resistant Gram-negative infections. Nontuberculous Mycobacteria (NTM) Infections, Medical, Dental and Vision Insurance Coverage, Short- and Long-Term Disability Insurance Coverage. The dark blue line represents the company's actual earnings per share. Ms. Joseph is also an independent director on the Board of BINA Farm Center, a therapeutic horseback riding association. Patheon was founded in Canada in 1974 as Custom Pharmaceuticals and changed its name in 1993, the year it went public in the Toronto Stock Exchange. Spero Therapeuticsis developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections. Prior to joining Spero, he was Vice President of Program and Portfolio Management at Cubist Pharmaceuticals. (844) 978-6257. This, together with his unique blend of experience within the biotech industry, at global pharmaceutical companies, and as an infectious disease physician, make him the ideal candidate to join Spero as CMO. March 30, 2023 16:05 ET Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat multi-drug resistant Gram-negative infections in the hospital setting. Ms. Tregoning graduated from Stanford University with a B.A. Based on its current operating plans, Spero believes that its cash and cash equivalents, together with other non-dilutive funding commitments, will be sufficient to fund its operating expenses and capital expenditure requirements beyond 2024. Spero Therapeutics (NASDAQ:SPRO) has a recorded annual revenue of $53.51 million. Earnings for Spero Therapeutics are expected to grow in the coming year, from ($1.05) to ($0.84) per share. The forward-looking statements included in this press release represent Speros views as of the date of this press release. Get to know our team of experts in the treatment of infectious disease. Your submission has been received! Latest Trade. The company's unique . She earned her M.B.A. from the Wharton School of the University of Pennsylvania, and a M.S. Cambridge, MA Type Public Company Founded 2013 Specialties Antibacterial Therapies, Novel Therapeutics, and Infectious Disease Locations Primary 675 Massachusetts Ave 14th Floor Cambridge, MA. in Economics from Harvard University and an M.B.A. in Finance and Strategy from Yale University. Named one of Bostons Best Places to Work in 2021, 2020, and 2017, Spero Therapeutics was also the recipient of the first-ever 2017 Xconomy Startup of the Year Award. Something went wrong while submitting the form. The primary endpoint of the trial will evaluate changes in bacterial load in sputum samples from baseline to the end of the trial's 56-day treatment period. The patent has a term extending into at least June 2039, without accounting for potential extensions. Before joining Spero, Dr. Hamed was the CMO of Lysovant Sciences and held senior positions in clinical development and medical affairs at Novartis (including Therapeutic Area Head for Anti-infectives), Bristol-Myers Squibb, and Bayer. Iceni Court, Delft Way, Spero Therapeutics last announced its earnings data on May 11th, 2023. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Enter your email address below to receive the latest news and earnings results for SPRO and its competitors with MarketBeat's FREE daily newsletter. Spero professionals share our companys ambitious focus on addressing unmet needs in infectious disease and helping to find solutions to treat patients who suffer from these infections. Real-time Estimate Tradegate - 10:25:24 2023 . The NDA submission includes previously communicated positive data from the Phase 3 ADAPT-PO trial. Initiation of the Phase 3 clinical trial is expected in the second half of 2023. Source: Bukhta Yurii / Shutterstock.com Let's get into. Prior to joining Celator Pharmaceuticals, Mr. Jackson held positions of increasing responsibility in sales, marketing and commercial development at multiple companies, including Eli Lilly & Company, SmithKline Beecham plc, ImClone Systems Incorporated, Centocor, Inc., a division of Johnson & Johnson, Eximias Pharmaceutical Corporation and YM BioSciences Inc. Mr. Jackson presently serves on the Board of Directors of MacroGenics, Inc. and GlycoMimetics, Inc. These statements include, but are not limited to, statements about the regulatory path forward for tebipenem HBr and potential FDA approval, the potential commercialization of tebipenem HBr and its future value, the potential receipt of milestone payments or royalties on under Speros various license and collaboration agreements, the design, initiation, timing, progress and results of Spero's preclinical studies and clinical trials and its research and development programs, and Spero's cash runway. Finally, tebipenem HBr has proven itself to be worthy of ongoing study and clinical development, given the market size for complicated urinary tract infection and the unmet patient need.. An archived webcast will be available on Spero's website for 30 days following the presentation. Get 30 Days of MarketBeat All Access Free, By creating a free account, you agree to our, 3 Dividend Stocks That Still Make Sense in 2023, Stock market today: World shares retreat after China reports weaker than expected growth in 2Q, China's economy misses growth forecasts, raising the odds of more support for its tepid recovery, United Health Stock Is Flying, It May Only Be The Beginning, Investors Like Adobe's Potential To Leverage Generative AI, Turkish President Erdogan heads to Persian Gulf states seeking funds for ailing economy, Joby Aviation Stock Moves Higher With Catalyst For More Growth. Mr. Thomas was a member of the Board of Directors of the Massachusetts Biotechnology Council from 2007 to 2015 and currently serves as a member of the Board of Directors of Zafgen, Inc., a public biopharmaceutical company, which he joined in June 2014. It focuses to design therapeutics using potent modalities . Bardell highlights findings in a recent report , +44 2078673717 Please log in to your account or sign up in order to add this asset to your watchlist. All rights reserved. Something went wrong while submitting the form. These expenses were primarily comprised of $8.6 million of severance and other employee costs, $2.4 million of discontinuation costs such as contract termination fees, and $0.6 million of lease impairment expenses. Lonza has four divisions: Capsules and Health Ingredients, Small Molecules, Biologics, and Cell & Gene Therapy, and Bioscience. SPRO Earnings Date and Information. Tim has close to 30 years experience in the pharmaceutical industry, spanning multiple functional and therapeutic areas. info@pharmaboardroom.com, For media inquiries, please contact: Mr. Jackson holds a B.S. This data showed that ADAPT-PO met its primary endpoint by demonstrating that oral tebipenem HBr was statistically non-inferior to IV ertapenem in the treatment of patients with cUTI and patients with acute pyelonephritis (AP). These statements include, but are not limited to, statements aboutthe potential approval of tebipenem HBr by the FDA;the timing of launch of tebipenem HBr;the potential number of patients who could be treated by tebipenem HBr and market demand for tebipenem HBr generally;theeffectiveness of tebipenem HBr andits potential impact on healthcare resource utilizations;and the anticipated shift from IV to oral administration. Dr. Hamed completed a residency in Internal Medicine at UMDNJRobert Wood Johnson Medical School and a fellowship in Infectious Diseases at Stanford University School of Medicine. Spero anticipates that subsequent events and developments will cause its views to change. Ankit Mahadevia, MD President and CEO Learn More Kamal Hamed, MD, MPH, MBA Norwich, NR6 6BB UK, We use cookies to ensure that we give you the best experience on our site. Frank Thomas has served as a member of our Board of Directors since July 2017. CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full-year ended December 31, 2022, and provided a business update. However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. With headquarters in Amsterdan, Netherlands, and Durham, North Carolina, the company has more than 55 locations around the globe, providing services through all phases of development, including API, biologics, viral vector services, formulation, clinical trial solutions, logistics services and commercial manufacturing. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Prior to joining Atlas in 2008, Ankit worked on product and business development with the founding team at Arcion Therapeutics. Earnings vs. Headwinds: Mixed Signals For S&P's 2023 Performance, 3 Stocks that Analysts Continue to Upgrade into Earnings Season. CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and. The chart below shows up to four years of a company's earnings history. From 1988 to 1991, he held a faculty position at Boston University Medical School. served as Senior Vice President and Chief Scientific and Medical Officer of ViiV Healthcare from November 2009 to October 2019, where he oversaw research and development, regulatory, safety and medical affairs. Milind joined Achillion in September 2001 as Vice President of Chemistry, was named Head of Drug Discovery in April 2002, Senior Vice President of Drug Discovery in December 2002, Senior Vice President and Chief Scientific Officer in December 2004, and Executive Vice President of Research and Chief Scientific Officer in June 2007. Can These 3 Stocks Soar On Triple-Digit Earnings Increases? Prior to Cornerstone, he worked for finance consulting firms LECG Corporation and Putnam, Hayes & Bartlett, Inc. Mr. Shukla earned a B.A. BlackRock Kicks Off Financials Earnings Season, Gauge To Markets, JPMorgan Chase Is In Reversal But Dont Chase It Higher, Nikola's Stock Surges On New Deals And Rising Short Interest, Get Your Cash Out of U.S. Banks Immediately, Skip Charts & View Estimated and Actual Earnings Data. Spero Therapeutics, Inc. News. Prior to that role, he also lead several of Cubists in-licensed development programs, and also lead the commercial supply chain for Cubicin. Preceding Lysovant, Kamal was Head of Clinical Development & Medical Affairs at Basilea Pharmaceutica International, and prior to Basilea, he had held senior positions in clinical development and medical affairs at Novartis Pharmaceuticals Corporation (including Therapeutic Area Head for Anti-infectives), Bristol-Myers Squibb, and Bayer Corporation, spearheading the successful global development, approval, and post-marketing medical affairs support of multiple anti-infectives. He also served on the Board of Trustees of the Eastern Pennsylvania Chapter of The Leukemia and Lymphoma Society from March 2013 to June 2019. Investor Contact: IR@sperotherapeutics.com Media Contact Media@sperotherapeutics.com Business Development Contact: BD@sperotherapeutics.com General Inquires: info@sperotherapeutics.com or at 857-242-1600 Office Location: 675 Massachusetts Avenue 14th Floor Cambridge, MA 02139 Contact Us Fill out the form to get in touch! Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) CAMBRIDGE, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset . Heluna Health is a population health non-profit with a focus on child and maternal nutrition, HIV prevention and homelessness. Kamal joins Spero with an impressive track record of building and leading successful anti-infective franchises, said Ankit Mahadevia, MD, Chief Executive Officer of Spero Therapeutics. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz- und Cookie-Einstellungen oder Datenschutz-Dashboard klicken. Report here. 2022 Spero Therapeutics. Research and development expenses for the fourth quarter of 2022 were $15.1 million, compared to $17.2 million of research and development expenses for the same period in 2021. Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update. in International Relations and holds an M.A. Real-time analyst ratings, insider transactions, earnings data, and more. In exchange for these rights, Spero is eligible to receive up to a total of $80 million in development and sales milestone payments, and high single-digit to low double-digit royalties on net sales of SPR206 in these territories. AboutSperoTherapeuticsSpero Therapeuticsis a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases. Using its integrated cell-free protein synthesis platform, XpressCF, to create a variety of protein therapeutics for cancer and autoimmune disorders. Get daily stock ideas from top-performing Wall Street analysts. The New York Times Reports: "No existing defense can stop it." General and administrative expenses for the fourth quarter of 2022 were $6.5 million, compared to $13.0 million of general and administrative expenses for the same period in 2021. Department of Defense Select SPR206 studies are supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Joint Warfighter Medical Research Program under Award No. While there, he was the program leader for ceftolozane/tazobactam, which progressed rapidly from Phase 1 to Phase 3, and was approved in the US in December of 2014. Learn why Spero has been named one of the 2021 Best Places to Work by the Boston Business Journal. The revenue increase for the year ended December 31 2022, was primarily due to the aforementioned partnership collaboration revenue. As of December 31, 2022, Spero had cash and cash equivalents of $109.1 million. Clinical trial diversity not only allows for a better understanding of the safety and efficacy of new therapies in population subgroups but also plays a significant role in reducing health, As the global pharmaceutical industry continues to grow, so have opportunities for service providers. Spero employees are passionate about antibiotic drug development and the mission of delivering life-saving drugs to patients suffering from multidrug-resistant infections and rare diseases. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. This is due to considerably lower manufacturing costs than in North America and Europe and favorable regulations. Our leadership team is approachable and transparent while encouraging of open lines of communication which, in turn, leads to confidence and a high degree of camaraderie built on a solid foundation of trust. During the meeting, the agency indicated that positive results from a single additional Phase 3 clinical trial supported by confirmatory nonclinical evidence of efficacy could be sufficient to support the approval of tebipenem HBr for the treatment of cUTI, including pyelonephritis for a limited use indication. Prior to his time at Lysovant, Dr. Hamed was Head of Clinical Development & Medical Affairs at Basilea Pharmaceutica. National Institute of Allergy and Infectious Disease Select SPR206 studies have been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. Our world-class team of biotechnology and biopharmaceutical experts embraces the Italian word spero which means hope. It is our mission to bring hope to patients and families of loved ones suffering from serious infections. Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on treatments using a novel therapeutic approach to treat bacterial infections and rare diseases. Spero Therapeutics is actively pursuing collaborations with non-commercial organizations and pharmaceutical partners for scientific expertise and funding support. Meet our highly knowledgeable and talented Board of Directors. Mr. It may be bold, but I think the success of Recipharm, in the beginning, may have contributed to the industry trend that we see of CDMOs today, at least on a [Swedish] local level Today we have a strong presence in almost every country in Western Europe and a significant footprint in India, where we made two acquisitions, while we also acquired a laboratory in Israel and development operations in the US. Openly transparent and highly respectful, our leadership team firmly believes that Spero Therapeutics employees are their most important and valued resource. Be Engaged. Prior to joining Achillion, Dr. Deshpande was Associate Director of Lead Discovery and Early Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb from 1991 to 2001, where he managed the identification of new clinical candidates to treat infectious and neurological diseases. Previously, he served in several organization development and effectiveness roles at Genzyme, a Sanofi Company, including Genzymes global biotechnology manufacturing and distribution operations. Initiation of a Placebo-controlled Phase 2 Trial of SPR720 in . Our Vice President, Alliance Management & Business Development, Akash Jain, spoke to young aspiring biotech professionals at the @jainaconvention 2023 summer program on July 1, sharing advice for advancing skills, expanding horizons through opportunities, & developing a career. To view a replay of the event, please click. Citigroup Leads Banking Earnings, What's Next? Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether the FDA will ultimately approve tebipenem HBr and, if so, the timing of any such approval; whether the FDA will require any additional clinical data or place labeling restrictions on the use of tebipenem HBr that would add costs for Spero, delay approval and/or reduce the commercial prospects of tebipenem HBr; whether any third parties would be interested in partnering with Spero to pursue continued efforts to obtain FDA approval of tebipenem HBr, or acquiring rights to the tebipenem HBr program from Spero through a partnership arrangement; the COVID-19 pandemic; Speros need for additional funding; the risk that Spero may not be able to address the FDA's concerns with respect to tebipenem HBr; the lengthy, expensive, and uncertain process of clinical drug development for SPR720 and SPR206; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; Speros reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; the ability to commercialize Speros product candidates, if approved; Speros ability to retain key personnel; whether Speros cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the Risk Factors set forth in filings that Spero periodically makes with the U.S. Securities and Exchange Commission. He has also held positions in business development both at Genentech and at Vanda Pharmaceuticals. Export data to Excel for your own analysis. in public policy from the Eagleton Institute of Politics at Rutgers University. The forward-looking statements included in this press release represent Spero's views as of the date of this press release. Investor Relations Contact:Ted JenkinsVice President, Head of Investor RelationsTjenkins@sperotherapeutics.com (617) 798-4039, Media Contact:media@sperotherapeutics.com. Add to a list. Prior to joining ZS Pharma, Ms. Smith served as Vice President, Market Access and Commercial Development at Affymax from 2008 to 2013. Spero team members are pioneers and emerging leaders in the anti-infective field. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. Do Good. A key objective of the trial is to provide clinical proof-of-concept for SPR720 by demonstrating its ability to drive microbiological response against NTM as a single agent versus placebo. For more information, visithttps://sperotherapeutics.com. Total revenues for the fourth quarter of 2022 were $47.4 million, compared with revenues of $2.7 million for the fourth quarter of 2021. Ankit began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor, and Pensions committees, the U.S. Government Accountability Office, and the Mexican Institute of Social Security (IMSS). Be Humble. Learn more on analysts' earnings estimate vs. SPRO's actual earnings. Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat multi-drug resistant Gram-negative infections in the hospital setting. Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. | Source: However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. He received his A.B. The chart below shows up to four years of a company's revenue history. In the latter role, she was responsible for the development and execution of integrated corporate affairs strategies through effective deployment of communications, patient advocacy, public policy, and government affairs on a global basis.Earlier in her career, Ms. Tregoning was a professional staff member for multiple committees in the United States Congress, and also served as an assistant deputy mayor for policy & budget in the office of the Mayor of Los Angeles. in biology from Colgate University and his M.D. Found a factual error? W81XWH 19 1 0295. Multiple external, non-dilutive funding sources have supported, or continue to support, the SPR206 program. Patrick Vink, M.D., M.B.A., aged 52, is currently an advisor to the Pharmaceutical industry since 2015 and non-executive Board member of several companies. To use this feature you must be a member. He holds an MD degree from the American University of Beirut, an MPH degree from Johns Hopkins University, and an MBA degree from the University of South Florida. The patent is assigned to Spero and covers the SPR206 composition of matter, formulations thereof, and methods of treating a bacterial infection with SPR206. Get the Latest News and Ratings for Your Stocks. Jamie comes to Spero Therapeutics from uniQure Therapeutics where he served as CHRO, and Intarcia Therapeutics, where he served as Vice President, Human Resources. Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Previously, he worked in the health care groups of McKinsey & Company and Monitor Group. She has led legal, compliance, human resources, public and government affairs, and risk management departments at life science companies in the US and in Europe for over 20 years. Spero and the FDA also achieved alignment on key components of the proposed pivotal Phase 3 trial design, which will be subject to a Special Protocol Assessment (SPA) agreement. Forward Looking StatementsThis press release may contain forward-looking statements. PDF Report. NEW YORK, July 21, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) and certain of . Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. Prior to his time at Lysovant, Dr. Hamed was Head of Clinical Development & Medical Affairs at Basilea Pharmaceutica. Spero Therapeutics is committed to advancing novel treatment approaches for bacterial infections. When is Spero Therapeutics's earnings date? Based in Sweden, Recipharm became part of the top five after its acquisition of Consort Medical in 2020 for a reported USD 707 million. PharmaBoardroom Limited What is Spero Therapeutics's EPS forecast for next year? Kamal Hamed, MD, MPH, MBA joined Spero as Chief Medical Officer (CMO) in September 2022. For more information, visit https://sperotherapeutics.com. The firm had revenue of $2.07 million for the quarter, compared to analyst estimates of $2 million.
Bcps Department Of Schools, Catholic Diocese Of Fort Worth Jobs, Jurupa Hills Country Club, Stringking Mark Strung Lacrosse H For Sale, Articles S